170 related articles for article (PubMed ID: 15902276)
1. Protein toxins: intracellular trafficking for targeted therapy.
Johannes L; Decaudin D
Gene Ther; 2005 Sep; 12(18):1360-8. PubMed ID: 15902276
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapy of cancer using diphtheria toxin-derived immunotoxins.
Potala S; Sahoo SK; Verma RS
Drug Discov Today; 2008 Sep; 13(17-18):807-15. PubMed ID: 18678276
[TBL] [Abstract][Full Text] [Related]
3. Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors.
Xia D; Moyana T; Xiang J
Cell Res; 2006 Mar; 16(3):241-59. PubMed ID: 16541123
[TBL] [Abstract][Full Text] [Related]
4. Coupled cellular trafficking and diffusional limitations in delivery of immunotoxins to multicell tumor spheroids.
Wenning LA; Murphy RM
Biotechnol Bioeng; 1999 Mar; 62(5):562-75. PubMed ID: 10099565
[TBL] [Abstract][Full Text] [Related]
5. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
Khawli LA; Hu P; Epstein AL
Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
[TBL] [Abstract][Full Text] [Related]
6. Immunotoxins in cancer therapy: Review and update.
Akbari B; Farajnia S; Ahdi Khosroshahi S; Safari F; Yousefi M; Dariushnejad H; Rahbarnia L
Int Rev Immunol; 2017 Jul; 36(4):207-219. PubMed ID: 28282218
[TBL] [Abstract][Full Text] [Related]
7. Novel genetic immunotoxins and intracellular antibodies for cancer therapy.
Chen SY; Marasco WA
Semin Oncol; 1996 Feb; 23(1):148-53. PubMed ID: 8607024
[TBL] [Abstract][Full Text] [Related]
8. Effective tumor targeting: strategies for the delivery of Armed Antibodies.
MacDonald GC; Glover N
Curr Opin Drug Discov Devel; 2005 Mar; 8(2):177-83. PubMed ID: 15782542
[TBL] [Abstract][Full Text] [Related]
9. Prevention of murine experimental autoimmune encephalomyelitis by in vivo expression of a novel recombinant immunotoxin DT390-RANTES.
Jia Y; Li H; Chen W; Li M; Lv M; Feng P; Hu H; Zhang L
Gene Ther; 2006 Sep; 13(18):1351-9. PubMed ID: 16708076
[TBL] [Abstract][Full Text] [Related]
10. T-cell receptor-like antibodies: novel reagents for clinical cancer immunology and immunotherapy.
Noy R; Eppel M; Haus-Cohen M; Klechevsky E; Mekler O; Michaeli Y; Denkberg G; Reiter Y
Expert Rev Anticancer Ther; 2005 Jun; 5(3):523-36. PubMed ID: 16250828
[TBL] [Abstract][Full Text] [Related]
11. Immunotoxins and cancer therapy.
Li Z; Yu T; Zhao P; Ma J
Cell Mol Immunol; 2005 Apr; 2(2):106-12. PubMed ID: 16191416
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic potential of anticancer immunotoxins.
Choudhary S; Mathew M; Verma RS
Drug Discov Today; 2011 Jun; 16(11-12):495-503. PubMed ID: 21511052
[TBL] [Abstract][Full Text] [Related]
13. The Shiga toxin B-subunit targets antigen in vivo to dendritic cells and elicits anti-tumor immunity.
Vingert B; Adotevi O; Patin D; Jung S; Shrikant P; Freyburger L; Eppolito C; Sapoznikov A; Amessou M; Quintin-Colonna F; Fridman WH; Johannes L; Tartour E
Eur J Immunol; 2006 May; 36(5):1124-35. PubMed ID: 16568496
[TBL] [Abstract][Full Text] [Related]
14. In vivo administration of plasmid DNA encoding recombinant immunotoxin DT390-IP-10 attenuates experimental autoimmune encephalomyelitis.
Chen W; Li H; Jia Y; Lv M; Li M; Feng P; Hu H; Zhang L
J Autoimmun; 2007 Feb; 28(1):30-40. PubMed ID: 17267177
[TBL] [Abstract][Full Text] [Related]
15. Targeting tumours by adoptive transfer of immune cells.
Macary PA; Too CT; Dai X
Clin Exp Pharmacol Physiol; 2006; 33(5-6):569-74. PubMed ID: 16700896
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxicity of human RNase-based immunotoxins requires cytosolic access and resistance to ribonuclease inhibition.
Erickson HA; Jund MD; Pennell CA
Protein Eng Des Sel; 2006 Jan; 19(1):37-45. PubMed ID: 16243897
[TBL] [Abstract][Full Text] [Related]
17. p53 as a target for anti-cancer immunotherapy.
Chen HL; Carbone DP
Mol Med Today; 1997 Apr; 3(4):160-7. PubMed ID: 9134529
[TBL] [Abstract][Full Text] [Related]
18. Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy.
Fassnacht M; Lee J; Milazzo C; Boczkowski D; Su Z; Nair S; Gilboa E
Clin Cancer Res; 2005 Aug; 11(15):5566-71. PubMed ID: 16061874
[TBL] [Abstract][Full Text] [Related]
19. [Immunotherapy with genetically modified tumor cells].
Topf N; Schmiegel WH
Internist (Berl); 1996 Apr; 37(4):374-81. PubMed ID: 8655274
[No Abstract] [Full Text] [Related]
20. Re-targeting of cytotoxic T lymphocytes and/or natural killer cells to CEA-expressing tumor cells with anti-CEA antibody activity.
Kuroki M; Hachimine K; Huang J; Shibaguchi H; Kinugasa T; Maekawa S; Kuroki M
Anticancer Res; 2005; 25(6A):3725-32. PubMed ID: 16302732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
